Department of Geriatric Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
J Korean Med Sci. 2023 Jun 19;38(24):e209. doi: 10.3346/jkms.2023.38.e209.
The ravages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide have sped up the development of relevant vaccines, which is accompanied by public concerns over possible adverse effects. We report a rare case of a 39-year-old woman who suffered from severe hyperglycemia and ketoacidosis with normal hemoglobin A1c four days after SARS-CoV-2 protein subunit vaccine, which is consistent with the diagnosis of fulminant type 1 diabetes (FT1D). She received insulin therapy and recovered after 24 days from onset of the symptoms. This is the first case of new-onset FT1D after SARS-CoV-2 protein subunit vaccination and one of only six that developed after any form of SARS-CoV-2 vaccination. We hope to raise awareness of this potential adverse consequence and recommend careful monitoring after vaccination in patients even without a medical history of diabetes.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在全球的肆虐加速了相关疫苗的研发，但这也引起了公众对可能出现的不良反应的担忧。我们报告了一例罕见的病例，一名 39 岁女性在接种 SARS-CoV-2 蛋白亚单位疫苗后四天出现严重高血糖和酮症酸中毒，但血红蛋白 A1c 正常，符合暴发性 1 型糖尿病（FT1D）的诊断。她接受了胰岛素治疗，症状出现后 24 天康复。这是首例 SARS-CoV-2 蛋白亚单位疫苗接种后新发的 FT1D，也是仅有的六例任何形式的 SARS-CoV-2 疫苗接种后发生的 FT1D 之一。我们希望提高对这种潜在不良后果的认识，并建议即使没有糖尿病病史的患者在接种疫苗后也要密切监测。
